Selected Publications
-
CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft modelsCell Reports Medicine, 2025The Intriguing Clinical Sucess of BCL-2 Inhibition in Acute Myeloid LeukemiaAnnual Review of Cancer Biology, 2021
2025
Cell-intrinsic Inflammation Shapes Cell-state Heterogeneity and Drives Therapeutic Resistance in Human Acute Myeloid LeukemiaLina Liu, Yin Zhao, Yue Liang, Jun Liu, Dawei Huo, Yu Shen, Wei Bian, Yanan Wang, Shang Lou, Xiaoqing Zou, Shijun Xiong, Diange Jin, Zeyuan Cai, Nuo Shen, Congxiao Zhang, Shaoqi Zhang, Wenyu Zhang, Rong Wang, Yutong She, Junyang Zeng, Yunzhi Kong, Yi Zhao, Weiyan Zheng, Yongxian Hu, Yi Luo, Yanmin Zhao, Jie Sun, Yishan Ye, He Huang*, Shanshan Pei* (*Co-corresponding). Cell-intrinsic Inflammation Shapes Cell-state Heterogeneity and Drives Therapeutic Resistance in Human Acute Myeloid Leukemia. 2025 EHA Oral Presentation.
Small-molecule inhibition of YTHDC1 as a strategy against acute myeloid leukemiaHailin Zhang, Yueshan Li, Yin Zhao, Falu Wang, Guifeng Lin, Ting Niu, He Li, Yueyue Li, Lina Liu, Yue Liang, Yu Shen, Yuyao Yi, Hui Zhou, Shang Lou, Yishan Ye, Yanmin He Ruicheng Yang, Rui Yao, Chenyu Tian, Pei Zhou, Mengdan Wu, Mingxin chen, Haixing Xu, Jing You, Yi Liao, Chenlu Yang, Ailin Zhao, Chong Chen, Linli Li*, Shanshan Pei*, Shengyong Yang* (*Co-corresponding). Small-molecule inhibition of YTHDC1 as a strategy against acute myeloid leukemia. Sci. Transl. Med. 2025. In press.
CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft modelsKai Shang, Deyu Huang, Jun Liu, Zebin Yu, Wei Bian, Jiangqing Chen, Yin Zhao, Lina Liu, Jie Jiang, Yajie Wang, Yanting Duan, Jingyu Ge, Shize Zhang, Chun Zhou, Yingli Han, Yongxian Hu, Weiyan Zheng, Jie Sun, He Huang*, Shanshan Pei*, Pengxu Qian*, Jie Sun* (*Co-corresponding). CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. Cell Rep Med. 2025 Jun 17;6(6):102148.2024
The TFG-ROS1 fusion Is an Oncogenic Driver of Human Myeloid LeukemiaJie Sun, Shaoqi Zhang, Ran Du, Yue Zang, Yongjin Liu, Zhihui Li, Diange Jin, Rong Fan, Lina Liu, Jun Liu, Yue Liang, Shang Lou, Xiaoqing Zou, Bian Wei, Yin Zhao, Rong Wang, Yanan Wang, Tong Wu*, Jinyan Huang*, Hongshan Guo*, Shanshan Pei* (*Co-corresponding). The TFG-ROS1 fusion Is an Oncogenic Driver of Human Myeloid Leukemia. 2024 ASH Oral Presentation.2023
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapyESI Top 1% Most cited articlesShanshan Pei*, Ian T Shelton, Austin E Gillen, Brett M Stevens, Maura Gasparetto, Yanan Wang, Lina Liu, Jun Liu, Tonya M Brunetti, Krysta Engel, Sarah Staggs, William Showers, Anagha Inguva Sheth, Maria L Amaya, Mohammad Minhajuddin, Amanda Winters, Sweta B Patel, Hunter Tolison, Anna E Krug, Tracy N Young, Jeffrey Schowinsky, Christine M McMahon, Clayton A Smith, Daniel A Pollyea, Craig T Jordan* (*Co-corresponding). A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discovery. 2023 Sep 6;13(9):2032-2049.2021
The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia
Daniel A. Pollyea#, Shanshan Pei#, Brett M. Stevens, Clayton A. Smith, and Craig T. Jordan*. (#Co-first author) The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia. Annu. Rev. Cancer Biol. 2021 Mar Vol. 5:277-289.
2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients
ESI Top 1% Most cited articles, AACR 2020-2021 Best Articles
Shanshan Pei, Pollyea S, Gustafson A, Stevens B, Minhajuddin M, Fu R, Riemondy K, Gillen A, Sheridan R, Kim J, Costello J, Amaya M, Inguva A, Winters A, Ye H, Krug A, Jones C, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers J, Ashton J, Nemkov T, D’Alessandro A, Gutman J, Fesik S, Ramsey H, Savona M, Smith C, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery . 2020. Apr;10(4):536-551.
2018
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Shanshan Pei, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018 Jul 5;23(1):86-100.e6.
OTHER PEER-REVIEWED PUBLICATIONS
Yuan X, Wu Y, Wang Y, Wu J, Zhu P, Yang L, Lai X, Liu L, Shi J, Yu J, Zhao Y, Zheng W, He J, Sun J, Wu W, Zhao Y, Cai Z, Huang H*, Pei S*, Luo Y* (*Co-corresponding). Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT. Ann Hematol . 2025 Oct 24.
Wu Y, Yuan X, Lai X, Liu L, Liang Y, Yang L, Zhu P, Shi J, Yu J, Zhao Y, Zheng W, Sun J, Zhu Y, Wu W, Cai Z, Huang H, Pei S*, Luo Y* (*Co-corresponding). KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia. Cancer . 2025 Jul 1;131(13):e35941.
Wu Y, Yuan X, Lai X, Liu L, Liang Y, Ni L, Yang L, Hu S, Shi J, Yu J, Zhao Y, Zheng W, Sun J, Zhu Y, Wu W, Cai Z, Huang H, Pei S*, Luo Y* (*Co-corresponding). Cellular hierarchy for understanding heterogeneity of acute myeloid leukaemia with t(8;21)/RUNX1-RUNX1T1. Clin Transl Immunology. 2025 Jul 2;14(7):e70042.
Li L, Zhu L, Xiong M, Chen Z, Luo Y, Shi J, Chen T, Zhao Y, Yu J, Lai X, Liu L, Fu H, Jin D, Zhang G, Pei S, Liang Y, Ye X, Ye Y, Zhang X, Huang H.
Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older. Bone Marrow Transplant.
2025 Jun;60(6):773-778. doi: 10.1038/s41409-025-02560-y. Epub 2025 Mar 30.
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica . 2025 Jan 1;110(1):103-116.
Zhao Y, Huo W, Liang Y, Mo X*, Pei S*, Zhao Y* (*Co-corresponding). Insights from TARGET-seq: Inflam mation drives TP53-mediated clonal evolution. Innovation . 2024 Jan 5;5(2):100572.
Sheth AI, Althoff MJ, Tolison H, Engel K, Amaya ML, Krug AE, Young TN, Minhajuddin M, Pei S, Patel SB, Winters A, Miller R, Shelton IT, St-Germain J, Ling T, Jones CL, Raught B, Gillen AE, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium. Cancer Discov . 2024 Oct 4;14(10):1922-1939.
Jin D, He J, Chen H, Wu W, Han X, Le J, Shu W, Yang Q, Pei S*, Cai Z*, He D* (*Co-corresponding). Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Cancer Med . 2024 Jul;13(14):e7378.
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood . 2022 Jan 27;139(4):584-596.
Pei S, Minhajuddin M, D’Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT*. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. The Journal of Biological Chemistry. 2016 Oct 14;291(42):21984-22000.
Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O’Dwyer MK, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT*. Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells. The Journal of Biological Chemistry. 2013, 288(47): 33542-58.
Nasim S#, Pei S#, Hagen FK, Jordan CT, Crooks PA*. Melampomagnolide B: A New Antileukemic Sesquiterpene. Bioorg Med Chem. 2011, 19(4): 1515-1519.
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022 Jan 27;139(4):584-596.
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 Dec 28;5(24):5565-5573.
Ye H, Minhajuddin M, Krug A, Pei S, Culp-Hill R, Ponder J, Deblooois E, Schniedewind B, Amaya M, Inguva A, Stevens B, Pollyea DA, Christians U, D’Alessandro A, Jordan CT. The Hepatic Microenvironment Uniquely Protects Leukemia Cells Through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discovery. 2020 Oct 7;CD-20-0318.
Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D’Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Gillen AE, Savona MR, Smith C, Jordan CT*. Fatty Acid Metabolism Mediates Venetoclax Resistance in Acute Myeloid Leukemia Stem Cells. Nature Cancer. 2020. 1176–1187(2020).
Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Gamboni F, Abbott D, DeGregoori J, Smith C, D’Alessandro A, Jordan CT*. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020. Aug. 14.
Jones CL, Stevens BM, D’Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, Degregori J, Pollyea DA, Jordan CT*. Cysteine Depletion Targets Leukemia Stem Cells Through Inhibition of Electron Transport Complex II. Blood. 2019 Jul 25;134(4):389-394.
Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D’Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho T, Kelly KK, Myers JR, Ashton JM, Siegenthaler JA, Kume T, Cambell EL, Pollyea DA, Becker MW, Jordan CT*. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Reports. 2019 April 2; 238-254.
Gasparetto M, Pei S, Minhajuddin M, Stevens B, Smith CA*, Seligman P*. Low Ferroportin Expression in AML is Correlated with Good Risk Cytogenetics, Improved Outcomes and Increased Sensitivity to Chemotherapy. Leukemia Research. 2019 Feb 28; 80:1-10.
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D’Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith CA, Jordan CT*. Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Acute Myeloid Leukemia Patients. Nature Medicine. 2018. Dec;24(12):1859-1866.
Jones CL, Stevens BM, D’Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Reinhold D, Smith CA, Degregori J, Pollyea DA, Jordan CT*. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018 Nov 12;34(5):724-740.e4.
Wang B, Lyu H, Pei S, Song D, Ni J, Liu B*. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle. 2018;17(8):985-996.
Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA*. Targeted Therapy for a Subset of Acute Myeloid Leukemias that Lack Expression of Aldehyde Dehydrogenase 1A1. Haematologica. 2017 Jun;102(6):1054-1065.
Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT*. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. 2016 Jul 7;19(1):23-37.
Smith KS, Yadav VK, Pei S, Pollyea DA, Jordan CT, De S*. SomVarIUS: Somatic variant identification from unpaired tissue samples. Bioinformatics. 2016, Mar 15;32(6):808-13.
Lim SJ, Scott A, Xiong XP, Vahidpour S, Karijolich J, Guo D, Pei S, Yu YT, Zhou R, and Li WX*. Requirement for CRIF1 in RNA interference and Dicer-2 stability. RNA biology. 2014, 11(9): 1171-9.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL*. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014, 511(7507): 90-3.
Lagadinou ED, Sach A, Callahan KP, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, O’Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT*. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013, 12(3): 329-341.
Du J, Cai X, Yao J, Ding X, Wu Q, Pei S, Jiang K, Zhang Y, Wang W, Shi Y, Lai Y, Shen J, Teng M, Huang H, Fei Q, Reddy ES, Zhu J, Jin C, Yao X*. The Mitotic Checkpoint Kinase NEK2A Regulates Kinetochore Microtubule Attachment Stability. Oncogene. 2008, 27(29): 4107-4114.
